Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: J Allergy Clin Immunol. 2016 Jan 22;138(1):262–273.e6. doi: 10.1016/j.jaci.2015.11.018

FIG 5.

FIG 5

A and B, Transfer of ALNCs from BALB/c, MyD88−/−, or IFN-γ−/− mice epicutaneously (EC) treated with OVA and CpG and its effect on production of OVA-specific IgE (Fig 5, A) and IgG2a (Fig 5, B) in recipients that underwent subsequent EC immunization and challenge with OVA. C and D, Role of IL-17A in OVA-specific IgG2a production: transfer of ALNCs from C57BL/6 or IL-17A−/− B6 donors EC immunized with OVA and CpG (Fig 5, C) and neutralization of IL-17A in recipients receiving ALNCs from BALB/c mice EC treated with OVA and CpG (Fig 5, D). Fig 5, A and B, n = 4–5; Fig 5, C, n = 7; Fig 5, D, n = 6–11. i.p ., Intraperitoneal. *P < .05, **P < .01, and ***P < .001.